Project Grant R01HL188013
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $693K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $249,000 on March 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct genomic and functional molecular analyses investigating the mechanistic links between clonal hematopoiesis of indeterminate potential (CHIP) and coronary artery disease (CAD). The recipient will discover further germline genetic predisposition that induces CHIP-related cardiovascular disease using an...
- The National Heart Lung and Blood Institute awarded Sloan-Kettering Institute For Cancer Research $169,020 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research on the role of ZBTB1 in normal and clonal hematopoiesis. The award funds a career development project investigating how epigenetic dysregulation of ZBTB1 drives clonal advantage in DNMT3A-mutant hematopoietic stem cells and contributes to clonal hematopoiesis, a premalignant condition...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1.137883 million on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the dynamics and plasticity of the hematopoietic stem cell niche. The funded work defines niche dynamics and plasticity across development, regeneration, and hematological disease; uncovers the mechanisms regulating these processes; and develops approaches to enhance...
- The National Heart, Lung, and Blood Institute awarded $1.175 million to Icahn School of Medicine at Mount Sinai on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate hemogenic mesoderm heterogeneity, regulation, and function in the developing mammalian hematopoietic system. The research, led by Dr. Sturgeon, delineates the molecular and transcriptional mechanisms by which hemogenic mesoderm gives rise to embryonic hematopoietic programs. The work...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $218,728 on March 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop computational and experimental methods for studying noncoding RNAs in hematopoiesis. The recipient will develop a computational pipeline to process and analyze single-cell total RNA sequencing (scTRS) data, a method that captures modified and non-polyadenylated noncoding RNAs—including long...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Albert Einstein College of Medicine $862,509 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanism and therapeutic targeting of RIPK3-driven cell death in reperfused myocardial infarction. The research dissects ZBP1-RIPK3 signaling pathways in myocardial ischemia-reperfusion injury to identify a single therapeutic target capable of inhibiting multiple...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $158,892 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the impact of DNMT3A protein reduction on normal and clonal hematopoiesis. The research investigates mechanisms by which somatic DNMT3A mutations drive clonal hematopoiesis—the clonal expansion of mutated hematopoietic stem and progenitor cells—which accelerates with age and increases the risk of hematologic...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $3.095 million on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance understanding of genetic variation's role in congenital heart disease causality and outcomes. The award funds a program project grant structured around four synergistic research projects supported by administrative and computational cores. Project 1 deepens understanding of genetic causality of...
- The National Heart, Lung, and Blood Institute awarded New York University $1,692,126 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect the molecular mechanisms and therapeutic potential of CHROMR, a long noncoding RNA upregulated in atherosclerotic cardiovascular disease. The research will map CHROMR-protein interfaces and design steric-blocking oligonucleotides to selectively disrupt the CHROMR-IRF2BP2 interaction, decoupling its pro-inflammatory...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $839,536 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how lifestyle factors selectively modify clonal hematopoiesis in atherosclerosis through immuno-metabolic reprogramming. The research will examine whether sleep and exercise—evolutionarily conserved behaviors that promote cardiovascular and immune health—can modify the evolution of clonal...